Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers
  • 4.9 (51)
  • MEDICINE

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

  1. How to Treat Metastatic NSCLC W/O Targeted Mutations – Treatment Algorithm with Dr. Christine Garcia

    3D AGO ·  VIDEO

    How to Treat Metastatic NSCLC W/O Targeted Mutations – Treatment Algorithm with Dr. Christine Garcia

    Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the treatment algorithm for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations in frontline settings. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We discussed the latest updates in lung cancer treatment, including the recent approval of Teliso-V for C-MET overexpressing disease and Zongertinib for HER2 positive cases. We explored the nuances of choosing between single-agent and dual checkpoint inhibitors, the role of PD-L1 scores, and the impact of molecular testing on treatment decisions. Special guest Dr. Christine Garcia, a thoracic medical oncologist and fellowship program director at Weill Cornell Medicine, shared her insights on the importance of biomarker testing, the implications of STK11 and KEAP1 mutations, and the evolving landscape of KRAS inhibitors. Key topics covered in this episode: The significance of NGS testing and PD-L1 scores in treatment decisions The role of chemotherapy in high PD-L1 patients Insights on dual checkpoint inhibitors based on recent clinical trials The latest options for KRAS G12C mutations and C-MET overexpression Practical considerations for managing treatment-related side effects Tune in for an informative discussion that bridges the gap between academic research and community practice in oncology. Don't forget to subscribe for more episodes on treatment algorithms and the latest in cancer care! #MetastaticNSCLC, #Immunotherapy, #KRASG12C, #BiomarkerTesting, #OncologyBrothers

    23 min
  2. How to Treat Localized Non-Small Cell Lung cancer – Treatment Algorithm with Dr. Sanjay Popat

    6D AGO ·  VIDEO

    How to Treat Localized Non-Small Cell Lung cancer – Treatment Algorithm with Dr. Sanjay Popat

    Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain dive deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with curative intent. Joined by leading thoracic medical oncologist Dr. Sanjay Popat from London, they discussed the critical role of next-generation sequencing (NGS) in treatment planning, the importance of proper staging, and the implications of actionable mutations. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics covered included: The significance of NGS testing and its impact on treatment decisions. Insights from the CHECKMATE 816 trial, highlighting the benefits of neoadjuvant chemoimmunotherapy. The complexities of post-operative immunotherapy and patient-shared decision-making. The role of adjuvant chemotherapy in patients with actionable mutations like EGFR and ALK. The latest data on osimertinib and alectinib in the adjuvant setting. The standard of care for unresectable disease based on the PACIFIC trial and the implications of PD-L1 status. Join us for an informative discussion that unpacks the latest advancements in NSCLC treatment and emphasizes the importance of personalized care. Don't forget to subscribe for more episodes in our treatment algorithm series! #EarlyStageNSCLC, #CHECKMATE816, #NeoadjuvantTherapy, #PrecisionMedicine, #OncologyBrothers

    26 min
  3. How to Treat Small Cell Lung Cancer (SCLC) – Treatment Algorithm with Dr. Jacob Sands

    APR 30 ·  VIDEO

    How to Treat Small Cell Lung Cancer (SCLC) – Treatment Algorithm with Dr. Jacob Sands

    Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Jacob Sands, a thoracic medical oncologist from Dana-Farber Cancer Institute, to discuss the current treatment algorithms for small cell lung cancer (SCLC). Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ We dived deep into the aggressive nature of SCLC and the meaningful advances in treatment over the past few years. Key topics included: • The role of surgery and adjuvant chemotherapy in early-stage SCLC. • Insights into the ADRIATIC study, which highlighted the efficacy of Durvalumab in limited-stage disease. • The debate surrounding prophylactic cranial irradiation (PCI) and its implications for patient care. • The latest findings from the IMforte study, showcasing the combination of Atezolizumab and Lurbinectedin as a new standard of care in extensive-stage SCLC. • The promising results of Tarlatamab in the second-line setting and its impact on overall survival. Join us as we explored these advancements and their potential to improve patient outcomes in the fight against small cell lung cancer. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology! #SmallCellLungCancer, #SCLC, #ADRIATIC, , #IMforte, #OncologyBrothers

    22 min
  4. Managing Toxicities of Colorectal Cancer Drugs / Systemic Therapy – Dr. Rona Yaeger

    APR 27 ·  VIDEO

    Managing Toxicities of Colorectal Cancer Drugs / Systemic Therapy – Dr. Rona Yaeger

    Welcome to the third episode of our three-part series on colorectal cancer! In this episode of the Oncology Brothers we are joined by Dr. Rona Yaeger, a medical oncologist from the Memorial Sloan Kettering Cancer Center. Together, we dived into the management of common side effects associated with systemic treatments for colorectal cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Episode Highlights: • Overview of 5-FU and capecitabine, including the importance of DPYD mutation testing and side effects like cytopenia, mucositis, and cardiac toxicity. • Discussion on the use of 5-FU bolus in both metastatic and adjuvant settings. • Insights into managing oxaliplatin-induced neuropathy and the potential benefits of oral cryotherapy. • Clinical pearls for irinotecan, including the management of diarrhea and cholinergic effects. • Considerations for using Bevacizumab, including risks of hypertension, proteinuria, and blood clots. • Tips for managing side effects of anti-EGFR agents like Cetuximab and Panitumumab, including rash and infusion reactions. • An overview of oral agents such as encorafenib, TAS-102, and Regorafenib, with a focus on dosing strategies and side effect management. Join us as we explore these critical topics and provide valuable insights for healthcare professionals managing colorectal cancer treatments. Don't forget to subscribe for more episodes! #ColorectalCancer, #SideEffectManagement, #DPYDtesting, #ChemotherapyToxicity, #SupportiveCare

    24 min
  5. BREAKWATER Study for BRAF V600E Mutated Colorectal Cancer – Encorafenib + Cetuximab + Chemotherapy

    APR 23 ·  VIDEO

    BREAKWATER Study for BRAF V600E Mutated Colorectal Cancer – Encorafenib + Cetuximab + Chemotherapy

    Welcome back to the Oncology Brothers podcast! In this second episode of our three-part series on colorectal cancer, we dived deep into the BRAF V600E mutation and its implications for metastatic colorectal cancer treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we discussed: The prevalence and outcomes associated with BRAF V600E mutations Recent advances in treatment options, including the BREAKWATER study The significance of biomarker testing and how it influences treatment decisions The new standard of care combining Encorafenib and Cetuximab with chemotherapy Management of overlapping side effects from targeted therapies Strategies for sequencing treatments in patients with MSI-high disease This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in colorectal cancer treatment. Don't miss out on the critical insights shared by our expert guest! Be sure to check out Part 1 of our series for an overview of the colorectal cancer treatment landscape, and stay tuned for Part 3, where we will focus on toxicity management and practical clinical pearls. Subscribe to our channel for more oncology insights and updates! This discussion was in support of an independent educational grant provided by Pfizer

    18 min
  6. How to Treat Colorectal Cancer – Treatment Algorithm with Dr. Smitha Krishnamurthi

    APR 20 ·  VIDEO

    How to Treat Colorectal Cancer – Treatment Algorithm with Dr. Smitha Krishnamurthi

    In this episode of the Oncology Brothers podcast, we kicked off a three-part series on colorectal cancer, starting with the current treatment algorithm. They are joined by Dr. Smitha Krishnamurthi, a GI medical oncologist from the Cleveland Clinic, who walks through the evolving standard of care from early-stage disease all the way to refractory metastatic settings. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Key topics discussed included: • The evolving role of ctDNA as both a prognostic and predictive tool in stage two and three colon cancer, including its utility in oligometastatic disease surveillance. • Neoadjuvant versus adjuvant immunotherapy in MSI-high resectable colon cancer, comparing the NICHE-2 and ATOMIC trial approaches and when to use each. • Single-agent versus dual checkpoint inhibition with Nivo-Ipi for MSI-high metastatic disease, based on CHECKMATE-8HW data showing a PFS hazard ratio of 0.21. • Sequencing strategies in RAS-mutant and RAS wild-type metastatic colorectal cancer, including the role of sidedness, anti-EGFR therapy, and refractory options like fruquintinib, TAS-102, and regorafenib. Join us for this comprehensive discussion on colorectal cancer management in 2026. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #ColorectalCancer, #MSIHigh, #BRAFV600E, #ctDNA, #GIOncology, #OncologyBrothers

    25 min
  7. How to Treat Pancreatic Cancer – Treatment Algorithm with Dr. Shubham Pant

    APR 16 ·  VIDEO

    How to Treat Pancreatic Cancer – Treatment Algorithm with Dr. Shubham Pant

    In this episode of the Oncology Brothers podcast, we dived deep into the complexities of pancreatic cancer treatment with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we explored: • The challenges of diagnosing and treating pancreatic cancer, particularly in metastatic settings. • The importance of germline testing and next-generation sequencing (NGS) in guiding treatment decisions. • The role of neoadjuvant and adjuvant therapies, including FOLFIRINOX and Gemcitabine-based regimens. • Strategies for managing borderline resectable disease and the significance of multidisciplinary care. • The critical aspect of supportive care, including the use of pancreatic enzyme replacement therapy. • Insights into treatment options for metastatic disease, including FOLFIRINOX, NALIRIFOX, and Gemcitabine-Nab-paclitaxel. • The emerging landscape of targeted therapies for KRAS mutations and the potential of pan-RAS inhibitors. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving treatment algorithms for pancreatic cancer. Don't forget to like, subscribe, and hit the notification bell for more discussions on cancer treatment and care! #PancreaticCancer, #KRASmutation, #NeoadjuvantTherapy, #SupportiveCare, #OncBrothers

    24 min
  8. How to Treat Biliary Tract Cancer – Treatment Algorithm with Dr. Suneel Kamath

    APR 9 ·  VIDEO

    How to Treat Biliary Tract Cancer – Treatment Algorithm with Dr. Suneel Kamath

    In this episode of the Oncology Brothers, we welcomed Dr. Suneel Kamath from the Cleveland Clinic to discuss the complex landscape of biliary tract cancer. While this cancer type is not the most common, it carries a poor prognosis, making it crucial for oncologists to stay informed about the latest treatment options. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explored: The role of surgery and adjuvant chemotherapy in early-stage biliary tract cancer. Frontline treatment strategies for metastatic disease, including insights from the TOPAZ-1 and KEYNOTE-966 studies. The importance of biomarker testing, including HER2, IDH1, and FGFR mutations, and how they influence treatment decisions. Management of side effects associated with various therapies, including immunotherapy and chemotherapy. The emerging landscape of targeted therapies and the need for more effective treatment options. Whether you're a medical professional or someone interested in oncology, this episode provides valuable insights into the current treatment algorithms and challenges in managing biliary tract cancer. Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #BiliaryTractCancer, #Cholangiocarcinoma, #Immunotherapy, #BiomarkerTesting, #OncologyBrothers

    22 min
See All (100)

4.9
out of 5
51 Ratings

About

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

Information

You Might Also Like